Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RALLY-MF: A Phase 1b/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of DISC-0974 in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

Next Previous
Trial Profile

RALLY-MF: A Phase 1b/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of DISC-0974 in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs DISC 0974 (Primary)
  • Indications Anaemia; Myelofibrosis
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms RALLY-MF
  • Sponsors Disc Medicine

Most Recent Events

  • 06 Dec 2025 According to Disc Medicine media release, initial data from the RALLY-MF Phase 2 trial, at the upcoming American Society of Hematology (ASH) Annual Meeting, which will be held in Orlando, FL on Saturday, December 6, 2025, 5:30 pm to 7:30pm EST.
  • 03 Nov 2025 According to Disc Medicine media release, initial data from the trial will be presented at the upcoming American Society of Hematology (ASH) Annual Meeting
  • 20 Oct 2025 According to Disc Medicine media release, initial data from ongoing phase 2 study in anemia of MF to be reported by year end and topline data expected in 2026, if positive, is anticipated to support discussion with regulatory agencies on registrational path.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top